This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A method of treating patients who have diseases characterized bone loss comprising the step of administering to said patient an amount of TRANCE/RANK inhibitors effective to inhibit osteoclastogenesis and/or osteoclast function, wherein said TRANCE/RANK inhibitor is a compound having the Formula I



Formula I

wherein:

R_1, and R_2 are, independently, selected from the group consisting of -H, - OCH_3, - CH_2CH_3, -*t*-butyl, 3-carboxy-4-chlorophenylamino, -N-$(CH_2CH_2OH)_2$, and -O(O)C-Ph;

R_3 is selected from the group consisting of -H, ethyl, -OCH3, -C1, Br, F, 3carboxy-4 chlorophenylamino, -N-$(CH_2CH_2OH)_2$, -*t*-butyl, and -OC(O)-Ph, and is not limited to attachment at any certain position on the phenyl ring to which it is attached; and

R_4 is selected from the group consisting of -Br,-Cl, and -F.

2. (Cancelled)

3. (Original) The method of claim 2 wherein R_3 is attached at either the 1 or 4 position of the phenyl ring.

4. (Previously Presented) The method of claim 1 wherein said TRANCE/RANK inhibitor is a compound having the Formula I wherein:

R_1, R_2, and R_3 are $-OCH_3$, R_3 is attached at the 4 position, R_4 is -Cl;

R_1, and R_2 are methyl, R_3 is ethyl, attached at the 4 position, R_4 is -Cl;

R_1, and R_2 are $-OCH_3$, R_3 is -Cl, attached at the 2 position, R_4 is -Cl;

R_1, and R_2 are $-OCH_3$ and R_3 is H, R_4 is -Cl;

R_1, is H, R_2 and R_3 are 3-carboxy-4-chlorophenylamino, and R_3 is attached at the 4 position, R_4 is -Cl;

R_1 and R_2 are $-N(CH_2CH_2OH)_2$, R_3 is Cl, attached at the 4 position, R_4 is -Cl;

R_1, R_2, and R_3 are *t*-butyl, R_3 is attached at the 4 position, R_4 is -Cl;

R_1, is $-OCH_3$, R_2 and R_3 are H, R_4 is Cl; or

R_1, R_2, and R_3 are benzoate, R_3 is attached at the 4 position, R_4 is Br.

5. (Currently amended) The method of claim 1 wherein said TRANCE/RANK inhibitor is selected from the group consisting <u>of:</u>

I-A  ,

I-B  ,

I-C  ,

I-D  ,

I-E  ,

I-F  ,

I-G 

,

I-H 

, and

I-I 

.

6. (Withdrawn/Currently amended) The method of claim 1 wherein said TRANCE/RANK inhibitor is a compound having the Formula II



Formula II

wherein:

R_1 is selected from the group consisting of –diphenylchloromethyl, -di(4chlorophenyl)chloromethyl, and 4-(diphenylchloromethyl)phenyl; and R_2, R_3, R_4 are independently selected from the group consisting of -Br, -Cl, and -F.

7. (Withdrawn) The method of claim 6 wherein R_2, R_3, and R_4 are each -Cl.

8. (Withdrawn/Currently amended) The method of claim 1 wherein the TRANCE/RANK inhibitor is selected from the group consisting of compounds:

II-A 

,

II-B 

,

II-C  , and

II-D  .

9. (Withdrawn/Currently amended) The method of claim 1 wherein said inhibitor is a compound having Formula III



Formula III

wherein:

R_1= $(NO_2)_2$,O(CO)CH3, OH, $O(CO)CH_3$, $O(CO)(CH_2)_2COOH$, $O(CO)CH_2Br$, $O(CO)CH_2CI$, $O(CO)CH_2N(CH_3)_3$, or OC_sH_9O;

R2= $CH_2O(N0_2)$, CHO, $CH_2O(N0_2)$, CN, CH_3, COOH, CHNOH, $CH_2O(CO)(CH_2)_2COOH$, $CHN(NH)CONH_2$, $CHN(NH)C_6H_5$, $CHN(CH_2)C_6H_5$, $CH_2N(CH_2)_2OH$, $CH_2NC_6H_5$, or $CH_2N(NH)CSNH_2$;

R_3= OH, or H;

R_4= CH_3;

R_5= OH;

R_6 = $C_4H_3O_2$, $N(NHCO)C_6H_4Cl$, $N(NHCO)C_6H_4F$, COOH, O, $COCH_3$, $CH(CH_3)(CH_2)_2COOH$, $CH(CH_3)(CH_2)_2COOCH_3$, $O(CO)C_6H_5$, or OH;

R_7 = $O(CO)CH_2N(CH_3)_3$, or $O(CO)CH_3$;

R_8 = OH;

R_9 = O, or OH; and ~~Rio = O~~
R_{10} = O.

10. (Withdrawn/currently amended) The method of claim 1 wherein the inhibitor is selected from the group consisting of compounds III-1 to III-31:

III-1	
III-2	
III-3	

III-4	
III-5	
III-6	

III-7	
III-8	

III-9	
III-10	

III-11	
III-12	

III-13	
III-14	
III-15	

III-16	
III-17	
III-18	

III-19	
III-20	
III-21	

III-22	
III-23	
III-24	

III-25	
III-26	
III-27	

III-28	
III-29	
III-30	
III-31	

.

11. (Withdrawn/currently amended) The method of claim 1 wherein said inhibitor is a compound having Formula IV



Formula IV

wherein:

R1 = $O(CO)(CH_2)_2COOH$, or $O(CO)CH_2Br$; and

R2 = $O(CO)(CH_2)_2COOH$, or $O(CO)CH_2Br$.

12. (Withdrawn/currently amended) The method of claim 1 wherein the inhibitor is selected from the group consisting of compounds



IV-1 and



IV-2

13. (Withdrawn/currently amended) The method of claim 1 wherein said inhibitor is a compound having Formula V



Formula V

wherein:

R_1 = O, OH, or $O(CO)CH_3$;

R_2 = $O(CO)CH_3$, OH, $CO(CH_3)$, or $CO(CH_2)O(CO)CH_3$;

R_3 = CH_3, or OH; and

R_4 = $O(CO)CH_2C_6H_4I$, or CH_3.

14. (Withdrawn/currently amended) The method of claim 1 wherein the inhibitor is selected from the group consisting of compounds

V-1  ,

V-2  ,

V-3  ,

V-4  , and

V-5  .

15. Canceled

16. (Withdrawn/Currently amended) The method of claim 1 wherein the inhibitor is selected fromthe group consisting of compounds

VI-1  and



VI-[[11]] 2 _____.

17. (Withdrawn/currently amended) The method of claim 1 wherein the inhibitor is selected from the group consisting of compounds



VII _____,



VIII _____,

IX  ,

X  ,

XI  , and



XII _____.

Claims 18-43: (Cancelled)